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Introduction {#sec005}
============

Chronic kidney disease (CKD) is a global public health problem that leads to poor health and high costs \[[@pone.0233233.ref001]\]. A cross-sectional survey of a national sample of Chinese adults showed that the overall estimated prevalence of CKD was 10.8% \[[@pone.0233233.ref002]\]. Therefore, a better understanding of the risk factors for impaired renal function would have a major impact on both clinical practice and public health.

High blood pressure (BP) has been identified as the leading risk factor for mortality worldwide and one of the most important risk factors for CKD \[[@pone.0233233.ref003], [@pone.0233233.ref004]\]. BP fluctuations may occur under the influence of various factors such as age, increased vascular stiffness, sympathetic nervous system activity, and nonadherence to treatment \[[@pone.0233233.ref005]\]. The link between visit-to-visit blood pressure variability (BPV) and morbidity or mortality events has been emphasized in recent years. A growing body of evidence has shown associations of BPV with stroke, cardiovascular disease, and all-cause mortality in high-risk populations \[[@pone.0233233.ref006]--[@pone.0233233.ref008]\]. In terms of renal outcomes, BPV is a strong risk factor for poor outcomes in patients undergoing hemodialysis \[[@pone.0233233.ref009]\]. Previous studies have found that increased BPV is a prognostic factor for the development, progression, and severity of renal outcomes \[[@pone.0233233.ref010]--[@pone.0233233.ref013]\]. Other studies have shown associations of BPV with renal outcomes, but have yielded inconsistent results \[[@pone.0233233.ref014], [@pone.0233233.ref015]\].

It is important to reduce the incidence of CKD by early identification of high-risk patients and modification of treatment-related risk factors. The impact of increases in BPV (i.e., above mean BP values) on the risk of CKD remains unclear. An improved understanding of this relationship might provide a potential novel target for prevention of CKD. Thus, this systematic review and meta-analysis of cohort studies was conducted to comprehensively assess the association between visit-to-visit BPV and the risk of CKD.

Materials and methods {#sec006}
=====================

Search strategy {#sec007}
---------------

This systematic review and meta-analysis was conducted in accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines \[[@pone.0233233.ref016]\]. Comprehensive searches were conducted in Medline, Embase, and the Cochrane Library (including the Cochrane Central Register of Controlled Trials) from the date of inception to 31 December 2019. The methodology complied with the Cochrane Handbook for Interventional Systematic Reviews \[[@pone.0233233.ref017]\]. The article was written in a manner that adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@pone.0233233.ref018]\]. The following search terms were used: "blood pressure variability," "chronic kidney disease," "nephropathy," and other comparable terms. Additionally, we manually searched the reference lists of the retrieved articles to identify additional possible clinical studies. The protocol for the meta-analysis was registered with PROSPERO (Website: <https://www.crd.york.ac.uk/PROSPERO>; Registration number: CRD42020149248).

Study eligibility {#sec008}
-----------------

Studies were included if the following criteria were fulfilled: (1) cohort design, including prospective cohort or retrospective cohort, or follow up study of randomized controlled trial; (2) the exposure of interest was BPV; (3) the outcome was CKD (including proteinuria, nephropathy, diabetic kidney disease, and end-stage renal disease); (4) quantitative estimates were reported for the adjusted relative risk (RR) and 95% confidence interval (95% CI) for CKD associated with BPV.

A study was excluded if the following criteria were met: (1) inclusion or exclusion criteria of the study were unclear or unreasonable; (2) insufficient data of interest were reported; (3) the study was a review, supplement, abstract only, commentary article, editorial, or grey literature. If relevant data from ≥2 articles were derived from the same cohort, only the study with a longer follow-up duration or larger population was included in this analysis. Discrepancies were resolved by discussion.

Extraction of data {#sec009}
------------------

Data from all included studies were extracted by two independent review authors (H.L. and J.X.). Discrepancies in data abstraction were resolved through discussion or by a third investigator (W.C.). Data extracted from studies included the following information: first author's name, publication year, country, database, study design, duration of follow-up, sample size, mean patient age, sex, outcomes, outcome definitions, BPV measurements (e.g., standard deviation \[SD\]; coefficient of variation \[CV\]; variability independent of the mean \[VIM\] of systolic BP, diastolic BP, or both), fully adjusted RRs, and 95% CIs.

Assessment of study quality {#sec010}
---------------------------

The quality in prognosis studies (QUIPS) tool is recommended for quality assessment in reviews of prognostic factors \[[@pone.0233233.ref019]\]. Two reviewers (H.L. and J.X.) assessed the risk of bias in individual studies independently using the QUIPS tool \[[@pone.0233233.ref020]\]. This tool assesses six domains for bias and applicability of the research question: study participation, study attrition, prognostic factor measurement, outcome measurement, study confounding, and statistical analysis and reporting. An overall rating for each domain is rated as "high", "moderate", or "low" risk of bias. Discrepancies were resolved by discussion.

Data synthesis and statistical analysis {#sec011}
---------------------------------------

All statistical analyses were conducted using Stata version 12 (Stata Corp., College Station, TX, USA). Risk estimates for each study were reported as odds ratio, risk ratio, or hazard ratio; these were presumed to be approximately equivalent for effect sizes \<2.5 and follow-up \<20 years and therefore were merged directly \[[@pone.0233233.ref006], [@pone.0233233.ref021], [@pone.0233233.ref022]\]. We used RR to measure the effect of the association between BPV and CKD. Risk estimates were pooled using a random effects model due to the observational design of the included studies.

To quantify the dose--response relationship between BPV and risk of renal disease, we calculated the RR for each unit increment in BPV in each study. For studies that reported risk estimates using ranges of BPV, we calculated the midpoint in each category by calculating the average of the lower and upper bounds. When the highest or lowest category was open-ended, we assumed that the open-ended interval was similar in length to the adjacent interval \[[@pone.0233233.ref023]\]. The generalized least-squares (GLST) method was used to estimate RRs \[[@pone.0233233.ref024], [@pone.0233233.ref025]\]. We treated BPV as a continuous variable and adopted linear models to calculate RRs for each 1 mmHg increase in BPV in each study. When RRs indicated specific intervals of BPV increments (e.g., 3 mmHg or 5 mmHg), RRs for a change of 1 mmHg were calculated with the corresponding root of the original value. For instance, if the reported RR for 5 mmHg increments was 1.20, the RR for 1 mmHg change would be the fifth root of 1.2, which is 1.04 \[[@pone.0233233.ref007], [@pone.0233233.ref026]\].

Heterogeneity among the included studies was evaluated using the Cochrane Q test and I^2^ statistic \[[@pone.0233233.ref027]\]. A value of I^2^ \>50% was considered indicative of a significant level of heterogeneity; stratified syntheses and sensitivity analyses were used to explore sources of heterogeneity. Stratified analyses were performed based on follow-up duration, country, population, or sample size. Publication bias was assessed using Egger's test \[[@pone.0233233.ref028]\]. A two-tailed P-value \<0.05 was considered statistically significant.

Results {#sec012}
=======

Literature search and characteristics of included studies {#sec013}
---------------------------------------------------------

The results of the literature search are summarized in [Fig 1](#pone.0233233.g001){ref-type="fig"}. Of 4186 references retrieved in our literature search, the titles and abstracts of 4051 publications indicated that they were clearly irrelevant; these irrelevant references were excluded. Thus, we obtained 135 full-text articles and fully reviewed them. Of these 135 articles, two described the same cohort study and presented overlapping data \[[@pone.0233233.ref029], [@pone.0233233.ref030]\]. Ultimately, 14 studies, with a total of 11,407,535 participants, fulfilled our inclusion criteria and were included in the research \[[@pone.0233233.ref010], [@pone.0233233.ref011], [@pone.0233233.ref013], [@pone.0233233.ref014], [@pone.0233233.ref031]--[@pone.0233233.ref040]\].

![Flowchart of literature search.](pone.0233233.g001){#pone.0233233.g001}

The characteristics of all selected studies are listed in [Table 1](#pone.0233233.t001){ref-type="table"}. Of the 14 studies, the mean follow-up duration ranged from 2.6 to 11.5 years, and the mean patient age ranged from 28 to 68 years. Seven of these studies were conducted in Asia (three in Japan, two in China, and one each in Korea and Iran); the remaining seven were conducted in North America and Europe. One of the studies enrolled participants in 20 countries from Asia, Australia, Europe, and North America \[[@pone.0233233.ref036]\]. The populations of the studies included the general population, patients with hypertension, patients with type two diabetes, and patients with type one diabetes. All studies reported adjusted estimates. S1 Table in [S1 Data](#pone.0233233.s001){ref-type="supplementary-material"} showed the results of quality assessments using the QUIPS tool. Most of the included studies were deemed to be low or moderate risk of bias. Two of the studies was judged to be moderate risk of bias \[[@pone.0233233.ref010], [@pone.0233233.ref011]\].

10.1371/journal.pone.0233233.t001

###### Characteristics of included cohorts.

![](pone.0233233.t001){#pone.0233233.t001g}

  Reference                                              Publication year                                                                               Country          Database                                                                          Study design    Population                          No of subjects   Duration of follow-up (year)   Mean age (year)   Males (%)   Outcome                   Definition
  ------------------------------------------------------ ---------------------------------------------------------------------------------------------- ---------------- --------------------------------------------------------------------------------- --------------- ----------------------------------- ---------------- ------------------------------ ----------------- ----------- ------------------------- ------------------------------------------------------------------------------------------------------------------------------------------
  Yu and colleagues \[[@pone.0233233.ref031]\]           2019                                                                                           China            Wonders Big data management and control platform                                  Retrospective   Type 2 diabetes mellitus patients   12630            3.9                            61.4              41.5        Diabetic kidney disease   International Classification of Disease, tenth version (ICD-10) codes or a diagnosis of 'diabetic kidney disease' in the medical records
  Viazzi and colleagues \[[@pone.0233233.ref032]\]       2019                                                                                           Italy            The Italian Association of Clinical Diabetologists initiative                     Retrospective   Type 2 diabetes mellitus patients   30851            4                              65                57          Chronic kidney disease    eGFR less than 60 ml/ min per 1.73 m2, a reduction at least 30% from baseline and a combination of either one of the above endpoints
  Li and colleagues \[[@pone.0233233.ref033]\]           2019                                                                                           China            The Renal Sub-study of the China Stroke Primary Prevention Trial                  Retrospective   Hypertensive patients               10051            4.4                            59.5              36.5        Chronic kidney disease    A decrease in eGFR ≧30% and to a level of \<60 mL/min/1.73 m2, or ESRD
  Rapid renal function decline                           An average decline in eGFR of ≧5 mL/min/1.73 m2 per year                                                                                                                                                                                                                                                                                                      
  Bae and colleagues \[[@pone.0233233.ref034]\]          2019                                                                                           Korea            The Korean National Health Insurance Service                                      Retrospective   General population                  8199089          7.89                           48.3              58.7        End-stage renal disease   ICD-10 codes, initiation of renal replacement therapy or kidney transplantation
  Sohn and colleagues \[[@pone.0233233.ref035]\]         2016                                                                                           USA              The US Department of Veterans Affairs healthcare system                           Retrospective   Diabetic patients                   208338           3.5                            53.7              95.4        Nephropathy               Identified using ICD-9-CM codes
  Ohkuma and colleagues \[[@pone.0233233.ref036]\]       2017                                                                                           20 countries     The ADVANCE-ON study                                                              Retrospective   Type 2 diabetes mellitus patients   9114             7.6                            68                58          Major renal events        Chronic renal-replacement therapy and death from renal disease
  Ceriello and colleagues \[[@pone.0233233.ref014]\]     2017                                                                                           Italy            The Italian Association of Clinical Diabetologists initiative                     Retrospective   Type 2 diabetes mellitus patients   11791            2.6--3.4                       NP                56.3        Albuminuria               Development of albuminuria in patients with normoalbuminuria at baseline
  GFR below 60 mL/min/1.73 m2                            Decrease in GFR below 60 mL/min/1.73 m2 in patients with GFR ≥ 60 mL/min/1.73 m2 at baseline                                                                                                                                                                                                                                                                  
  Whittle and colleagues \[[@pone.0233233.ref037]\]      2016                                                                                           USA              The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial   Retrospective   Hypertensive patients               21245            3.5                            66.6              54.7        End-stage renal disease   Identified using the US Renal Data System
  ≥50% decline in eGFR                                                                                                                                                                                                                                                                                                                                                                                                 
  Gosmanova and colleagues \[[@pone.0233233.ref038]\]    2016                                                                                           USA              The cohort of U.S. veterans                                                       Retrospective   U.S. veterans                       2865157          4.9                            60                94          End-stage renal disease   Initiation of renal replacement therapy
  Yano and colleagues \[[@pone.0233233.ref039]\]         2015                                                                                           Japan            The Specific Health Check and Guidance System                                     Prospective     General population                  48587            3                              61.7              39          Chronic kidney disease    The presence of proteinuria or eGFR\<60 mL/min per 1.73 m2
  Takao and colleagues \[[@pone.0233233.ref040]\]        2014                                                                                           Japan            Hospital-based cohort                                                             Retrospective   Type 2 diabetes mellitus patients   664              11.5                           \-                \-          Nephropathy               Development of microalbuminuria, i.e., UAE ≥30 mg/g Cr
  Progression of nephropathy                             Decrease of eGFR to \<45 ml/min/1.73 m2                                                                                                                                                                                                                                                                                                                       
  Noshad and colleagues \[[@pone.0233233.ref011]\]       2014                                                                                           Iran             Hospital-based cohort                                                             Retrospective   Type 2 diabetes mellitus patients   194              2.6                            51.7              52.1        Microalbuminuria          UAE between 30 and 299 mg per 24 h in at least two consecutive urinary protein measurements
  Okada and colleagues \[[@pone.0233233.ref010]\]        2013                                                                                           Japan            Hospital-based cohort                                                             Retrospective   Type 2 diabetes mellitus patients   354              3.76                           65.5              61.6        Albuminuria               UAE \>30 mg per 24 h
  Kilpatrick and colleagues \[[@pone.0233233.ref013]\]   2010                                                                                           United Kingdom   The Diabetes Control and Complications Trial                                      Retrospective   Type 1 diabetes mellitus patients   1261             9                              28                60.3        Nephropathy               The development of an AER≥40 mg/24 h (28 μg/ min) on any annual evaluation, providing that the baseline AER was \<40 mg/24 h (28μg/min)

Association between visit-to-visit BPV and risk of CKD {#sec014}
------------------------------------------------------

Visit-to-visit systolic BPV (SBPV) was defined using SD, CV, and VIM. The risk of CKD was significantly greater in patients with high baseline SBPV than in patients with low baseline SBPV (SD \[RR = 1.69, 95% CI: 1.38--2.08; I^2^ = 98.8%; S1 Fig in [S1 Data](#pone.0233233.s001){ref-type="supplementary-material"}\], CV \[RR = 1.23, 95% CI: 1.12--1.36; I^2^ = 91.1%; S2 Fig in [S1 Data](#pone.0233233.s001){ref-type="supplementary-material"}\], and VIM \[RR = 1.40, 95% CI: 1.15--1.71; I^2^ = 95.9%; S3 Fig in [S1 Data](#pone.0233233.s001){ref-type="supplementary-material"}\]).

Furthermore, we calculated the combined RR (95% CI) for CKD based on increases in BPV. For each 1 mmHg increase in systolic BP SD, the combined RR for CKD was 1.05 (95% CI: 1.03--1.07) with significant heterogeneity (I^2^ = 86.3%) ([Fig 2](#pone.0233233.g002){ref-type="fig"}). For each 1% increase in systolic BP CV, the combined RR for CKD was 1.06 (95% CI: 1.03--1.09) with significant heterogeneity (I^2^ = 71.4%) ([Fig 3](#pone.0233233.g003){ref-type="fig"}). For each unit increase in systolic BP VIM, the combined RR for CKD was 1.1 (95% CI: 0.96--1.25) with significant heterogeneity (I^2^ = 88.4%) ([Fig 4](#pone.0233233.g004){ref-type="fig"}).

![Forest plot of relationship between 1 mmHg increment in SD-SBP and risk of CKD.\
Boxes represent the Relative risk (RR) and lines represent the 95% Confidence Intervals (CIs) for individual studies. The area of each square is proportional to study weight. The diamonds and their width represent the pooled RRs and the 95% CIs, respectively.](pone.0233233.g002){#pone.0233233.g002}

![Forest plot of relationship between 1% increment in CV-SBP and risk of CKD.\
Boxes represent the Relative risk (RR) and lines represent the 95% Confidence Intervals (CIs) for individual studies. The area of each square is proportional to study weight. The diamonds and their width represent the pooled RRs and the 95% CIs, respectively.](pone.0233233.g003){#pone.0233233.g003}

![Forest plot of relationship between 1 increment in VIM-SBP and risk of CKD.\
Boxes represent the Relative risk (RR) and lines represent the 95% Confidence Intervals (CIs) for individual studies. The area of each square is proportional to study weight. The diamonds and their width represent the pooled RRs and the 95% CIs, respectively.](pone.0233233.g004){#pone.0233233.g004}

Visit-to-visit diastolic BPV (DBPV) was defined using SD and CV. The risk of CKD was significantly greater in patients with high baseline DBPV than in patients with low baseline DBPV (SD \[RR = 1.14, 95% CI: 1.05--1.24; I^2^ = 88.7%; S4 Fig in [S1 Data](#pone.0233233.s001){ref-type="supplementary-material"}\] and CV \[RR = 1.18, 95% CI: 0.99--1.41; I^2^ = 95.6%; S5 Fig in [S1 Data](#pone.0233233.s001){ref-type="supplementary-material"}\]). Only one study reported DBPV using VIM; thus, we did not perform meta-analysis on the relationship of diastolic BP VIM with CKD. The combined RR (95% CI) per 1 mmHg increase in diastolic BP SD for CKD was 1.06 (95% CI: 1.01--1.11) with significant heterogeneity (I^2^ = 83.2%) ([Fig 5](#pone.0233233.g005){ref-type="fig"}). For each 1% increase in diastolic BP CV, the overall RR was 1.06 (95% CI: 1.03--1.09) with significant heterogeneity (I^2^ = 71.4%) ([Fig 6](#pone.0233233.g006){ref-type="fig"}).

![Forest plot of relationship between 1 mmHg increment in SD-DBP and risk of CKD.\
Boxes represent the Relative risk (RR) and lines represent the 95% Confidence Intervals (CIs) for individual studies. The area of each square is proportional to study weight. The diamonds and their width represent the pooled RRs and the 95% CIs, respectively.](pone.0233233.g005){#pone.0233233.g005}

![Forest plot of relationship between 1% increment in CV-DBP and risk of CKD.\
Boxes represent the Relative risk (RR) and lines represent the 95% Confidence Intervals (CIs) for individual studies. The area of each square is proportional to study weight. The diamonds and their width represent the pooled RRs and the 95% CIs, respectively.](pone.0233233.g006){#pone.0233233.g006}

Stratifying analysis {#sec015}
--------------------

We performed subgroup analysis of the studies based on follow-up duration, country, population, and number of subjects ([Table 2](#pone.0233233.t002){ref-type="table"}). In these analyses, the association of systolic BP SD with CKD remained; however, the heterogeneity also remained. The observational design of the studies might have been the major source of heterogeneity.

10.1371/journal.pone.0233233.t002

###### Subgroup analyses of 1mmHg increment in SD-SBP and risk of CKD.

![](pone.0233233.t002){#pone.0233233.t002g}

                       Subgroup   Studies, No.       RR (95% CI)        Heterogeneity
  -------------------- ---------- ------------------ ------------------ ---------------
  Follow-up duration   ≤5         4                  1.03(1.01, 1.05)   76.5%
  \>5                  3          1.07(1.02, 1.12)   77.0%              
  Country              Asia       3                  1.11(1.00, 1.23)   86.0%
  Non-Asia             3          1.05(1.00, 1.10)   92.9%              
  Population           Diabetic   5                  1.07(1.02, 1.12)   90.3%
  Non-diabetic         2          1.03(1.02, 1.04)   0.0%               
  No. of subjects      ≤10000     3                  1.07(1.02, 1.12)   77.0%
  \>10000              4          1.03(1.01, 1.05)   76.5%              

Bias and sensitivity analysis {#sec016}
-----------------------------

There was no evidence of publication bias regarding the BPV SD for CKD, as determined by Egger's linear regression test ([Fig 7](#pone.0233233.g007){ref-type="fig"}). The results remained consistent during sensitivity analysis, indicating that the meta-analysis was stable ([Fig 8](#pone.0233233.g008){ref-type="fig"}).

![Publication bias using Egger test.](pone.0233233.g007){#pone.0233233.g007}

![The sensitivity analysis regarding the BPV SD for CKD.](pone.0233233.g008){#pone.0233233.g008}

Discussion {#sec017}
==========

To the best of our knowledge, this is the first systematic review and meta-analysis to explore the potential relationship between visit-to-visit BPV and CKD. Our study demonstrated that high visit-to-visit BPV may indicate an increased risk of CKD. Patients with higher SBPV had a 5% higher risk of CKD for each 1 mmHg increase in SD compared to patients with lower SBPV. We also used CV and VIM to examine the association between SBPV and risk of CKD; the corresponding risk ratios also showed increased risk of CKD. This association remained significant in analysis of the relationship between visit-to-visit DBPV and the risk of CKD. Our results suggest that visit-to-visit BPV is an important clinical factor for predicting CKD.

BP is a physiological parameter that reflects hemodynamic status, and it is characterized by significant changes over time. The magnitude of BP variation was initially suspected to interfere with the accuracy of BP status assessments in individual patients. However, BPV is increasingly recognized as an important pathophysiological phenomenon. Visit-to-visit BPV is presumed to reflect a variety of mechanisms, such as fluctuations in activation of the renin--angiotensin--aldosterone system, overactivity of the central sympathetic nervous system, increased secretion of vasoactive compound, and/or increased arterial stiffness, as well as environmental and psychological conditions (e.g., physical activity and psychological stress) \[[@pone.0233233.ref005]\]. BPV is a powerful marker of cardiovascular and renal complications regardless of average BP level \[[@pone.0233233.ref041]\]. In previous studies, increased visit-to-visit BPV, independent of the mean BP, was linked to increases in all-cause mortality, as well as fatal and non-fatal cardiovascular disease events in the general population \[[@pone.0233233.ref042]--[@pone.0233233.ref044]\]. A significant relationship has been reported between the progression of renal insufficiency and higher visit-to-visit BPV in patients with CKD \[[@pone.0233233.ref045], [@pone.0233233.ref046]\].

Even mild renal impairment constitutes a prominent risk factor for cardiovascular disease, infection, cognitive impairment, and reduced physical function \[[@pone.0233233.ref047]\]. Our findings suggest that visit-to-visit BPV is an independent predictor of early renal impairment. Potential biological mechanisms underlying the relationship between visit-to-visit BPV and CKD may include fluctuations in renal blood flow, changes in aortic hypertrophy and remodeling, onset of endothelial dysfunction, activation of the renin--angiotensin system, activation of inflammatory cytokines, changes in oxidative stress or extracellular matrix deposition, and onset of glomerular sclerosis \[[@pone.0233233.ref048]--[@pone.0233233.ref052]\].

Several limitations might have contributed to the significant heterogeneity detected in this meta-analysis. Differences in population, sample size, follow-up duration, incomplete matching, country of origin, or methodology may have caused heterogeneity; of these factors, the observational study design of the included studies might have been the most prominent source. Methodological factors including number of visits, time interval between visits, and assessments by different doctors may have also contributed to the heterogeneity.

Taken together, the findings in this systematic review and meta-analysis suggest that increased visit-to-visit SBPV is an independent risk factor for CKD. However, significant heterogeneity was present; thus, future prospective studies are needed to confirm our findings. Our current findings indicate that treatment of hypertension should control BP levels and prevent abnormal fluctuations in BP to restore normal BP rhythm. Additional clinical studies are needed to evaluate the normal reference values of visit-to-visit BPV for clinical practice and identify more effective treatment approaches for reduction of BPV.
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